Biology of Blood and Marrow Transplantation
Volume 16, Issue 7 , Pages 1025-1031 , July 2010

Donor-Derived Second Hematologic Malignancies after Cord Blood Transplantation

Received 22 October 2009 ,Accepted 16 February 2010.

References 

  1. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl M Med. 2004;351:2255–2275
  2. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276–2285
  3. Eapen M, Rocha V, Scaradavou A, et al. Effect of stem cell source on transplant outcomes in adults with acute leukemia: a comparison of unrelated bone marrow (BM), peripheral blood (PB), and cord blood (CB). Blood. 2008;112:151a;[abstract]
  4. Takahashi S, Ooi J, Tomoran A, et al. Comparative single institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. 2007;109:1322–1330
  5. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007;110:3064–3070
  6. Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007;13:82–89
  7. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105:1343–1347
  8. Socie G, Mary JY, Schrezenmeier H, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2007;109:2794–2796
  9. Mori H, Colman SM, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA. 2002;99:8242–8247
  10. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897–904
  11. Lowe T, Bhatia S, Somlo G, et al. Second malignancies after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:1121–1134
  12. Rizzo JD, Curtis RE, Socie G. Solid cancers after allogeneic hematopoietic stem cell transplantation. Blood. 2009;113:1175–1183
  13. Cooley LD, Sears DA, Udden MM, et al. Donor cell leukemia: report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature. Am J Hematol. 2000;63:46–53
  14. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208–2216
  15. Baker KS, DeFor TE, Burns LJ, et al. New malignancies after blood or marrow stem cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21:1352–1358
  16. Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus–related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood. 2006;108:2874–2880
  17. Flynn CM, Kaufman DS. Donor cell leukemia: insight into cancer stem cells and the stem cell niche. Blood. 2007;109:2688–2692
  18. Brunstein CB, Hirsch BA, Hammerschmidt D, et al. Leukemia in donor cells after allogeneic stem cell transplant. Bone Marrow Transplant. 2002;29:999–1003
  19. Cutting RJ, Welch E, Channer J, et al. Myelofibrosis as the initial presentation of donor-derived myelodysplastic syndrome/AML: failure of a lasting response to a second allogeneic transplant from the original donor. Bone Marrow Transplant. 2008;42:631–633
  20. Fraser CJ, Hirsch BA, Dayton V, et al. First report of donor cell–derived acute leukemia as a complication of umbilical cord blood transplantation. Blood. 2005;106:4377–4380
  21. Ando T, Yujiri T, Mitani N, et al. Donor cell–derived acute myeloid leukemia after unrelated umbilical cord blood transplantation. Leukemia. 2006;20:744–745
  22. Matsunaga T, Murase K, Yoshida M, et al. Donor cell–derived acute myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T-cell lymphoma. Am J Hematol. 2005;79:294–298
  23. Konuma T, Ooi J, Takahashi S, et al. Donor cell–derived myelodysplastic syndrome after cord blood transplantation. Bone Marrow Transplant. 2009;43:429–431
  24. Cutler C, Mitrovich R, Kao G, et al. Double umbilical cord blood transplantation with reduced-intensity conditioning and sirolimus-based GVHD prophylaxis. Blood. 2007;118:2016a;[abstract]
  25. Rubinstein P, Dobrila L, Rosenfield RE, et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA. 1995;92:10119–10122
  26. Haspel RL, Kao G, Yeap BY, et al. Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant. 2008;41:523–529
  27. Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–1154
  28. Fine JP, Gray RJ. A proportional hazard model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509
  29. Barker JN, Weisdorf DJ, DeFor TE, et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced intensity conditioning. Blood. 2003;102:1915–1919
  30. Clave E, Agbalika F, Bajzik V, et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution, and rituximab therapy. Transplantation. 2004;77:76–84
  31. Wagner HJ, Cheng YC, Huls H, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004;103:3979–3981
  32. Knight JS, Tsodikov A, Cibrik DM, et al. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol. 2009;27:3354–3362
  33. Hou HA, Yao M, Tang JL, et al. Poor outcome in posttransplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years experience in a single institute. Bone Marrow Transplant. 2009;43:315–321
  34. Ocheni S, Kroeger N, Zabelina T, et al. EBV reactivation and posttransplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant. 2008;42:181–186
  35. Hale D, Waldmann H. Risk of developing Epstein-Barr virus–related lymphoproliferative disorders after T-cell–depleted marrow transplants: CAMPATH users. Blood. 1998;91:3079–3083
  36. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000;95:807–814
  37. Heslop HE. How I treat EBV lymphoproliferation. Blood. 2009;114:4002–4008
  38. Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide, and antithymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005;36:947–950
  39. Gallagher G, Forest DL. Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer. 2007;109:84–92
  40. Curtis RE, Metayer C, Rizzo JR, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood. 2005;105:3802–3811
  41. Janin A, Murata H, Leboeuf C, et al. Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation. Blood. 2009;113:1834–1840
  42. Greaves MF. Cord blood donor cell leukemia in recipients. Leukemia. 2006;20:1633–1634
  43. Armand P, Antin JH. Allogeneic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant. 2007;13:505–516
  44. Ditschkowski M, Haferlach C, Schulte C, et al. Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT. Bone Marrow Transplant. 2009;44:265–266

 Financial disclosure: See Acknowledgments, page 1030.

PII: S1083-8791(10)00085-6

doi: 10.1016/j.bbmt.2010.02.014

Biology of Blood and Marrow Transplantation
Volume 16, Issue 7 , Pages 1025-1031 , July 2010

Article Tools

* Image Usage & Resolution